Who to call at SCYNEXIS, Inc., and when
Fundz watches for the moments SCYNEXIS, Inc. starts buying, and tells you who to reach.
- An alert the day SCYNEXIS, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at SCYNEXIS, Inc., from your own LinkedIn network
SCYNEXIS, Inc.
The company signed a major contract or deal. An 8-K is the notice a US public company must file within four business days of a major event.
www.scynexis.comAI Executive Summary
AI-powered analysis of 8-K filing content
SCYNEXIS secured up to $214 million in non-dilutive funding from BARDA to develop SCY-247, an antifungal candidate, with an initial $18.5 million allocation for Phase 2 studies in invasive candidiasis. This strategic partnership significantly de-risks the company's clinical development pathway and provides substantial capital without equity dilution.
Key Takeaways
BARDA contract provides up to $214 million in non-dilutive funding, eliminating near-term financing pressure and reducing shareholder dilution risk
Initial $18.5 million funds advancement of SCY-247 into Phase 2 study for invasive candidiasis, a high-unmet-need indication
2 more takeaways
Related Filings (1)
1 more filing from SCYNEXIS, Inc. in the last 90 days
Filing Overview
What This Means
SCYNEXIS, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.